India-EU dispute on drug seizure resolved

Image
Press Trust of India Berlin
Last Updated : Jan 21 2013 | 5:24 AM IST

India today said it has resolved a dispute with European Union over seizure of Indian generic drugs by some European countries, and will soon withdraw a complaint filed before the WTO on the matter.

"EU has accepted our position and amended their rules. We have got understanding on this issue," Commerce and Industry Minister Anand Sharma told reporters here on the sidelines of the FICCI-Frauenhofer CEOs Roundtable.

Asked whether India will withdraw its complaint from the WTO, the Minister said: "Yes. We do not want to be in conflict. There has been realisation and we appreciate the steps which have been taken (amending the EU rules). They went to the extent of saying that they were misreading the concerned EU notification."

India had dragged the 27-nation European bloc to the WTO after several instances of drug seizure on the high seas of Europe, ostensibly on the ground that the consignments violated EU laws.

However, India insisted that the drugs, which were being shipped to Latin American and African countries, were off- patent and there was no violation of any international law.

At the behest of WTO, officials from the two sides held two rounds of mutual consultations to resolve the disputes which had left a bitter taste for the $20 billion Indian pharmaceutical industry.

Sharma said that India is very firm on the issue of its Intellectual Property Rights (IPR) regime and would not go beyond its domestic legislation.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 07 2010 | 3:54 PM IST

Next Story